NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $24.04 +2.07 (+9.42 %) (As of 05/24/2019 04:00 PM ET)Previous Close$24.04Today's Range$21.91 - $24.3052-Week Range$9.67 - $24.30Volume5.42 million shsAverage Volume1.89 million shsMarket Capitalization$2.28 billionP/E RatioN/ADividend YieldN/ABeta2.15 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Receive ARWR News and Ratings via Email Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR Previous Symbol CUSIPN/A CIK879407 Webhttp://www.arrowheadpharma.com/ Phone626-304-3400Debt Debt-to-Equity RatioN/A Current Ratio2.31 Quick Ratio2.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio35.35 P/E GrowthN/A Sales & Book Value Annual Sales$16.14 million Price / Sales141.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book11.34Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-54,450,000.00 Net Margins10.09% Return on Equity6.72% Return on Assets4.25%Miscellaneous Employees116 Outstanding Shares94,814,000Market Cap$2.28 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The biotechnology company earned $48.15 million during the quarter, compared to analyst estimates of $45.78 million. Arrowhead Pharmaceuticals had a return on equity of 6.72% and a net margin of 10.09%. View Arrowhead Pharmaceuticals' Earnings History. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals. What price target have analysts set for ARWR? 6 analysts have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their predictions range from $11.68 to $33.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $23.8633 in the next twelve months. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Arrowhead Pharmaceuticals. What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals. Has Arrowhead Pharmaceuticals been receiving favorable news coverage? Media stories about ARWR stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY) and Nektar Therapeutics (NKTR). What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), Sasol (SSL), Sarepta Therapeutics (SRPT), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Opko Health (OPK), Exelixis (EXEL), Netflix (NFLX) and Micron Technology (MU). Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the folowing people: Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)Dr. Bruce D. Given, Chief Operating Officer (Age 65)Mr. Patrick O'Brien, Gen. Counsel (Age 55)Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (8.28%), BlackRock Inc. (8.10%), First Manhattan Co. (5.23%), FMR LLC (1.81%), Fiera Capital Corp (1.65%) and Goldman Sachs Group Inc. (1.32%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals. Which major investors are selling Arrowhead Pharmaceuticals stock? ARWR stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, First Trust Advisors LP, First Manhattan Co., Goldman Sachs Group Inc., 361 Capital LLC, Blair William & Co. IL, Fiera Capital Corp and FMR LLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals. Which major investors are buying Arrowhead Pharmaceuticals stock? ARWR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Charles Schwab Investment Management Inc., JPMorgan Chase & Co., Northern Trust Corp, AQR Capital Management LLC and Morgan Stanley. View Insider Buying and Selling for Arrowhead Pharmaceuticals. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $24.04. How big of a company is Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has a market capitalization of $2.28 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe. What is Arrowhead Pharmaceuticals' official website? The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected] MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 351 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 619MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.